Clinical trials prove Indian Covaxin vaccine effective

The third phase of the clinical trials of the Indian vaccine Covaxin has come to an end, the results of which proved that it protected about 77.8% of patients from an explicit form of COVID-19 infection, and about 65% from the delta variant of SARS-CoV-2, Report informs, citing TASS.

As researchers maintain, patients tolerated the vaccine well, and no major safety concerns were registered.

Covaxin (BBV152) is being developed by Bharat Biotech. This is a classic vaccine based on a weakened version of the SARS-CoV-2 virus, which poses no threat to the human body, but at the same time, helps the immune system to "remember" the real pathogen of COVID-19. Clinical trials of the drug began in July 2020.

Nearly 26,000 people, who received two doses of the vaccine every month, were involved in the recent clinical trials.